Loading clinical trials...
Loading clinical trials...
A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control
PF-06372865 in subjects with photosensitive epilepsy
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States
Johns Hopkins University Department of Neurology
Baltimore, Maryland, United States
Barnes Jewish Hospital
St Louis, Missouri, United States
Center for Advanced Medicine
St Louis, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
New York University Comprehensive Epilepsy Center
New York, New York, United States
Clinical and Translational Research Center
Philadelphia, Pennsylvania, United States
Hospital of the Univ of PA Pharmacy Service
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Comprehensive Epilepsy Center
Philadelphia, Pennsylvania, United States
Start Date
December 16, 2015
Primary Completion Date
January 10, 2017
Completion Date
February 7, 2017
Last Updated
March 14, 2018
7
ACTUAL participants
PF-06372865
DRUG
Placebo
DRUG
Lorazepam
DRUG
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions